548795-07-9

Upstream product

• 100-39-0 benzyl bromide 
• 249612-97-3 (3aS,4R,8R,8aS)-4,8-Bis-(4-ethyl-benzyl)-2,2-dimethyl-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 
• 548795-04-6 (R)-1-{(4S,5S)-5-[(R)-1-Amino-2-(4-ethyl-phenyl)-ethyl]-2,2-dimethyl-[1,3]dioxolan-4-yl}-2-(4-ethyl-phenyl)-ethylamine 
• 548795-01-3 N'-[1-{5-[1-(N',N'-dimethyl-hydrazino)-2-(4-ethyl-phenyl)-ethyl]-2,2-dimethyl-[1,3]dioxolan-4-yl}-2-(4-ethyl-phenyl)-ethyl]-N,N-dimethyl-hydrazine 

Downstream Products

• 548795-14-8 5-[(3aS,4R,8R,8aS)-7-Benzyl-4,8-bis-(4-ethyl-benzyl)-2,2-dimethyl-6-oxo-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl]-2-fluoro-benzonitrile 
• 548795-22-8 (3aS,4R,8R,8aS)-5-(3-Amino-1H-indazol-5-ylmethyl)-7-benzyl-4,8-bis-(4-ethyl-benzyl)-2,2-dimethyl-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 

Relevant academic research and scientific papers

Synthesis, antiviral activity and pharmacokinetics of P1/P1′ substituted 3-aminoindazole cyclic urea HIV protease inhibitors

A series of P1/P1′ substituted cyclic urea analogues were prepared in an attempt to increase the intra-cellular antiviral potency of the nonsymmetrical 3-aminoindazoles DMP 850 and DMP 851. The effect of alkyl substitution of the P1/P1′ residues on cellul